VIVS News and Press, VivoSim Labs Inc. From 10/30/25

A look at the top 10 most actives in the United States Intensity Therapeutics Inc. (INTS) rose 394.6% to $1.32 on volume of 1,376,488,997 shares Harvard Bioscience Inc. (HBIO) rose 41.1% to $0.63 on volume of 301,574,010 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 3.7% to...

A look at the top 10 most actives in the United States Intensity Therapeutics Inc. (INTS) rose 173.4% to $0.7297 on volume of 385,641,574 shares Cambium Networks Corporation (CMBM) rose 88.1% to $5.55 on volume of 100,908,607 shares Harvard Bioscience Inc. (HBIO) rose 23.1% to $0.5498 on vo...

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D ...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Kyndryl Holdings Inc. (KD) is expected to report $0.25 for Q1 2026 Bruker Corporation (BRKR) is expected to report $0.33 for Q2 2025 Vornado Realty Trust (VNO) is expected to report $0.53 for Q2 2025 Diamondback Energy Inc. (FANG) is expected to report $2.63 for Q2 2025 Freightcar...

Finch Therapeutics Group Inc. (FNCH) is expected to report for quarter end 2025-03-31 Huize Holding Ltd - ADR (HUIZ) is expected to report for Q1 2025 Biomerieux (BMXMF) is expected to report for quarter end 2025-03-31 Glucose Health Inc (GLUC) is expected to report for Q1 2025 CI...

180 Degree Capital Corp. (TURN) is expected to report for Q1 2025 Weir Group plc ADR (WEGRY) is expected to report for Q1 2025 ThermoGenesis Holdings Inc. (THMO) is expected to report for Q1 2024 Segro Plc (SEGXF) is expected to report for Q1 2025 Nutriband Inc. (NTRB) is expected...

VivoSim Labs Inc. (VIVS) is expected to report for Q4 2025

2025-05-20 05:47:34 ET Summary Here's the next batch of weird science stocks that have market darling potential. I’m tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature s...

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award...